Table 2.
Clinicopathological characteristics of early-stage NSCLC patients with different MIC-1 levels, n (%)
| Factors | Total Patients (n = 152) | Patients with MIC-1 <1465 pg/ml (n = 94) | Patients with MIC-1 ≥1465 pg/ml (n = 58) | Patients with MIC-1 <1465 pg/ml vs. patients with MIC-1 ≥1465 pg/ml | |
|---|---|---|---|---|---|
| χ2 | P | ||||
| Gender | 15.357 | 0.001 | |||
| Male | 63 (41.5) | 49 (52.1) | 14 (24.1) | ||
| Female | 89 (58.5) | 45 (47.9) | 44 (75.9) | ||
| Age | 11.863 | <0.001 | |||
| <60 years | 64 (42.1) | 53 (56.4) | 11 (19.0) | ||
| ≥60 years | 88 (57.9) | 41 (43.6) | 47 (81.0) | ||
| Smoking history | 7.812 | 0.057 | |||
| <20 years | 83 (54.6) | 57 (60.6) | 26 (44.8) | ||
| ≥20 years | 69 (45.4) | 37 (39.4) | 32 (55.2) | ||
| Tumor size | 1.517 | 0.011 | |||
| <3 cm | 105 (69.1) | 72 (76.6) | 33 (56.9) | ||
| ≥3 cm | 47 (30.9) | 22 (23.4) | 25 (43.1) | ||
| Histological type | 4.835 | 0.210 | |||
| Squamous cell | 36 (23.7) | 19 (20.2) | 17 (29.3) | ||
| Adenocarcinoma | 116 (76.3) | 75 (79.8) | 41 (70.7) | ||
| Differentiation | 3.367 | 0.102 | |||
| Moderate-well | 38 (25.0) | 28 (29.8) | 10 (17.2) | ||
| Poor | 114 (75.0) | 66 (70.2) | 48 (82.8) | ||
| T stage | 5.317 | 0.034 | |||
| T1 | 42 (27.6) | 32 (34.0) | 10 (17.2) | ||
| T2 | 101 (66.5) | 57 (60.6) | 44 (75.9) | ||
| T3 | 9 (5.9) | 5 (5.3) | 4 (6.9) | ||
| N stage | 0.763 | 0.156 | |||
| N0 | 124 (81.6) | 80 (85.1) | 44 (75.9) | ||
| N1 | 24 (15.8) | 12 (12.8) | 12 (20.7) | ||
| N2 | 4 (2.6) | 2 (2.1) | 2 (3.4) | ||
| Stage | 0.245 | 0.026 | |||
| I | 98 (64.5) | 67 (71.3) | 31 (53.4) | ||
| II | 54 (35.5) | 27 (28.7) | 27 (46.6) | ||
| Survival | 5.906 | 0.002 | |||
| Yes | 134 (88.2) | 89 (94.7) | 45 (77.6) | ||
| No | 18 (11.8) | 5 (5.3) | 13 (22.4) | ||
| Recurrence/metastasis | 1.942 | 0.107 | |||
| No | 118 (77.6) | 77 (81.9) | 41 (70.7) | ||
| Yes | 34 (22.4) | 17 (18.1) | 17 (29.3) | ||
MIC-1: Macrophage inhibitory cytokine-1; NSCLC: Nonsmall cell lung cancer; *Mann-Whitney U test.